IntelGenx Technologies (IGXT) 10-K 11 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 08, 2014	Jun. 30, 2013
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Trading Symbol	'igxt	'	'
Entity Registrant Name	'IntelGenx Technologies Corp.	'	'
Entity Central Index Key	'0001098880	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	62,600,656	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Well Known Seasoned Issuer	'No	'	'
Entity Public Float	'	'	$28,352,182
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current	'	'
Cash and cash equivalents	$5,005	$2,059
Accounts receivable	144	1,282
Prepaid expenses	133	102
Investment tax credits receivable	268	213
Total Current Assets	5,550	3,656
Leasehold Improvements and Equipment	588	387
Intangible Assets	79	116
Total Assets	6,217	4,159
Current	'	'
Accounts payable and accrued liabilities	593	1,058
Deferred license revenue	308	308
Total Current Liabilities	901	1,366
Deferred License Revenue, non-current portion	308	615
Total Liabilities	1,209	1,981
Commitments	'	'
Shareholders' Equity	'	'
Capital Stock	1	0
Additional Paid-in-Capital	20,934	16,342
Accumulated Deficit	-16,102	-14,463
Accumulated Other Comprehensive Income	175	299
Total Shareholders' Equity	5,008	2,178
Total Liabilities and Stockholders Equity	$6,217	$4,159

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (USD $)	Capital Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
In Thousands, except Share data
Beginning Balance at Dec. 31, 2011	$0	$15,918	($12,213)	$199	$3,904
Beginning Balance (Shares) at Dec. 31, 2011	48,895,028	'	'	'	'
Foreign currency translation adjustment	'	'	'	100	100
Warrants exercised	'	233	'	'	233
Warrants exercised (Shares)	726,080	'	'	'	'
Agents warrants exercised	'	104	'	'	104
Agents warrants exercised (Shares)	219,313	'	'	'	'
Options exercised	'	28	'	'	28
Options exercised (Shares)	50,000	'	'	'	'
Stock-based compensation	'	59	'	'	59
Net loss for the period	'	'	-2,250	'	-2,250
Ending Balance at Dec. 31, 2012	0	16,342	-14,463	299	2,178
Ending Balance (Shares) at Dec. 31, 2012	49,890,421	'	'	'	'
Foreign currency translation adjustment	'	'	'	-124	-124
Issue of common stock, net of transaction costs of $387	'	1,808	'	'	1,808
Issue of common stock, net of transaction costs of $387 (Shares)	7,920,346	'	'	'	'
Warrants issued, net of transaction costs of $230	'	1,075	'	'	1,075
Agents' Warrants	'	100	'	'	100
Warrants exercised	1	1,464	'	'	1,465
Warrants exercised (Shares)	3,098,500	'	'	'	'
Options exercised	'	31	'	'	31
Options exercised (Shares)	75,000	'	'	'	'
Stock-based compensation	'	114	'	'	114
Net loss for the period	'	'	-1,639	'	-1,639
Ending Balance at Dec. 31, 2013	$1	$20,934	($16,102)	$175	$5,008
Ending Balance (Shares) at Dec. 31, 2013	60,984,267	'	'	'	'

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Revenues	'	'
Royalties	$188	$0
License and other revenue	760	1,198
Total Revenues	948	1,198
Expenses	'	'
Research and development expense	561	1,723
Selling, general and administrative expense	1,954	1,689
Depreciation of tangible assets	34	37
Amortization of intangible assets	38	9
Total Costs and Expenses	2,587	3,458
Loss from Operations	-1,639	-2,260
Other Income	'	'
Interest and other income	0	10
Total Other Income	0	10
Loss Before Income Taxes	-1,639	-2,250
Income taxes	0	0
Net Loss	-1,639	-2,250
Other Comprehensive Income (Loss)	'	'
Foreign currency translation adjustment	-124	100
Comprehensive Loss	($1,763)	($2,150)
Basic and Diluted Weighted Average Number of Shares Outstanding	54,023,739	49,637,908
Basic and Diluted Loss Per Common Share	($0.03)	($0.04)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Funds Provided (Used) - Operating Activities	'	'
Net loss	($1,639)	($2,250)
Amortization and depreciation	72	46
Stock-based compensation	114	59
Total Adjustments	-1,453	-2,145
Changes in assets and liabilities	'	'
Accounts receivable	1,138	-1,019
Prepaid and other assets	-31	-34
Other receivables	-55	247
Accounts payable and other accrued liabilities	-465	390
Deferred revenue	-307	923
Net change in assets and liabilities	280	507
Net cash used by operating activities	-1,173	-1,638
Financing Activities	'	'
Issuance of common stock and warrants	3,500	0
Proceeds from exercise of warrants, agents' warrants and stock options	1,496	365
Transaction costs	-517	0
Net cash provided by financing activities	4,479	365
Investing Activities	'	'
Additions to leasehold improvements and equipment	-266	-270
Net Cash used in investing activities	-266	-270
Increase (Decrease) in Cash and Cash Equivalents	3,040	-1,543
Effect of Foreign Exchange on Cash and Cash Equivalents	-94	97
Cash and Cash Equivalents	'	'
Beginning of Year	2,059	3,505
End of Year	$5,005	$2,059

Basis_of_Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Basis of Presentation [Text Block]	'
	1	Basis of Presentation
		IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
		The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.
		The financial statements are expressed in U.S. funds.

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2013
Nature of Business [Text Block]	'
	2	Nature of Business
		The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies.
		Technologies
		The Company has developed three proprietary delivery platforms; including an immediate release oral film “ VersaFilm™ ”, a mucoadhesive tablet “ AdVersa™ ” and a multilayer controlled release tablet “ VersaTab™ ”.
		The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds.
		Product Pipeline
		IntelGenx’ product pipeline currently consists of 12 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 5 utilize the VersaFilm™ technology, 4 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology. In accordance with contractual commitments and for reasons of confidentiality, the Company is unable to disclose either the indicated treatment or the delivery platform behind two of the products under development.
		Approved and Commercialized Products
		The Company’s first FDA-approved product, Forfivo XL®, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL® is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in Wellbutrin XL®.

Adoption_of_New_Accounting_Sta

Adoption of New Accounting Standards	12 Months Ended
	Dec. 31, 2013
Adoption of New Accounting Standards [Text Block]	'
	3	Adoption of New Accounting Standards
		In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011-11. ASU 2011-11 and ASU 2013-01 are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.
		In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011-05 and 2011-12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Text Block]	'
	4	Summary of Significant Accounting Policies
		Revenue Recognition
		The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.
		IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.
		In August 2010, the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $800 thousand, of which $200 thousand was received by the Company in 2013 upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration. RedHill is required to make additional milestone payments of $500 thousand upon receipt of FDA marketing approval for the product, together with royalties and / or a share of profits upon commercialization.
		In December 2011, the Company entered into a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par"), a US company, for a generic formulation of buprenorphine and naloxone Sublingual Film, utilizing the Company’s VersaFilm™ technology. The reference listed drug is Suboxone® (buprenorphine and naloxone) Sublingual Film and is indicated for the maintenance treatment of opioid dependence. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $500 thousand, of which $250 thousand was received by the Company in 2013 following successful completion of the pivotal bioequivalence study. The agreement provides for additional, undisclosed, milestone payments, together with a share of profits upon commercialization.
		In February 2012, the Company entered into a license agreement with Edgemont Pharmaceuticals LLC (“Edgemont”), a US company, for the commercialization Forfivo XL®™ in the United States. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $2 million, and will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $26.5 million.
		Product Sales:
		The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $171 thousand in 2013.
		Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $308 thousand in 2013 and has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.
		Use of Estimates
		The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.
		Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
		Cash and Cash Equivalents
		Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.
		Accounts Receivable
		The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2013 accounts receivable (2012 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.
		Investment Tax Credits
		Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.
		Leasehold Improvements and Equipment
		Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:
		On the declining balance method -
		Laboratory and office equipment	20%
		Computer equipment	30%
		On the straight-line method -
		Leasehold improvements	over the lease term
		Manufacturing equipment	5 – 10 years
	Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
	Intangible Assets
	Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
	Impairment of Long-lived Assets
	Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.
		Foreign Currency Translation
		The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:
	Assets and liabilities - at exchange rates in effect at the balance sheet date;
	Revenue and expenses - at average exchange rates prevailing during the year;
	Equity - at historical rates.
	Gains and losses arising from foreign currency translation are included in other comprehensive income.
	Income Taxes
	The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	Unrecognized Tax Benefits
	The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
	Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
		Share-Based Payments
		The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.
		The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.
		Loss Per Share
		Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.
		Fair Value Measurements
		ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		Level 1:	Quoted market prices in active markets for identical assets or liabilities.
		Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
		Level 3:	Unobservable inputs that are not corroborated by market data.
	In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2013.
	Fair Value of Financial Instruments
	The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
	Recent Accounting Pronouncements
	In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
		In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
		In April 2013, the FASB issued Update No. 2013-07, “Presentation of Financial Statements – Liquidation Basis of Accounting”. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entitles should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.
		In July 2013, the FASB issued Update No. 2013-11, “Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption and retrospective application is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	12 Months Ended
	Dec. 31, 2013
Leasehold Improvements and Equipment [Text Block]	'
	5	Leasehold Improvements and Equipment
								2013		2012
		In US$ thousands				Accumulated		Net Carrying		Net Carrying
				Cost		Depreciation		Amount		Amount
		Manufacturing equipment	$	446	$	0	$	446	$	225
		Laboratory and office equipment		398		277		121		153
		Computer equipment		46		35		11		9
		Leasehold improvements - current premises		58		58		0		0
		Leasehold improvements - future premises		10		0		10		0
			$	958	$	370	$	588	$	387
		As of December 31, 2013 no depreciation has been recorded on manufacturing equipment as the equipment is not, to date, being utilized by the Company.
		Leasehold improvements carried out on our current premises have been fully depreciated. IntelGenx has invested approximately $10 thousand related to leasehold improvement activities for new premises that the Company intends to occupy later in 2014. No depreciation for this asset has been recorded as the premises are not, to date, being utilized by the Company.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Intangible Assets [Text Block]	'
	6	Intangible Assets
		As of December 31, 2013 NDA acquisition costs of $79 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012.

Deferred_License_Revenue

Deferred License Revenue	12 Months Ended
	Dec. 31, 2013
Deferred License Revenue [Text Block]	'
	7	Deferred License Revenue
		Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.
		Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments [Text Block]	'
	8	Commitments
		The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410 - 6420 Abrams. In the first half of 2014, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 16,000 of rentable square feet. The term of the amended lease will be 10 years following relocation, which is expected to commence in the second half of 2014 upon completion of certain leasehold improvements.
		As of December 31, 2013 future minimum payments under operating leases for facilities for the next 6 months are approximately $15 thousand.
		On October 1, 2009, the Company signed an agreement with Little Gem Life Science Partners for investor relation services in the USA. Under the terms of the agreement, the Company was required to pay $4.5 thousand per month to Little Gem Life Science Partners. The Company renegotiated the agreement in May 2012 and reduced payments to $2.5 thousand per month. The agreement automatically renews unless specifically terminated.
		On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL®, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL® in October 2012, the Company is required, after recovering an aggregate $200 thousand for management fees previously paid, to pay its former development partner 10% of net sales royalties received under the commercialization agreement that was executed with Edgemont Pharmaceuticals in February 2012. As of December 31, 2013 the Company has recovered approximately $147 thousand of said management fees.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2013
Capital Stock [Text Block]	'
	9	Capital Stock
				2013		2011
		Authorized -
		100,000,000 common shares of $0.00001 par value
		20,000,000 preferred shares of $0.00001 par value
		Issued -
		60,984,267 (December 31, 2012 - 49,890,421) common shares	$	610	$	499
	On December 16, 2013, as part of a registered public offering, the Company issued approximately 7.9 million shares of common stock at $0.4419 per share, and five-year warrants to purchase up to approximately 7.9 million shares of common stock, for aggregate gross proceeds of approximately US$3.5 million. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 60 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $1,808 thousand. (See note 10 for the portion allocated to the warrants).
	The Company paid an agent cash commissions in the amount of approximately $210 thousand, representing 6% of the aggregate gross proceeds received by the Company, plus expenses in the amount of approximately $35 thousand, and issued warrants to the agent to purchase 475,221 shares of common stock, representing 6% of the amount of shares sold in the public offering. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 48 months after the date of issuance.
	In addition, the Company paid approximately $272 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values.
	In the year ended December 31, 2013 a total of 75,000 (2012 – 50,000) stock options were exercised for 75,000 (2012 – 50,000) common shares having a par value of $0 thousand (2012 - $Nil) in aggregate, for cash consideration of $31 thousand ($28 thousand), resulting in an increase in additional paid-in capital of $31 thousand (2012 – $28 thousand).
	During the year ended December 31, 2013 no agents’ warrants were exercised. During the year ended December 31, 2012 a total of 219,313 agents’ warrants were exercised for 219,313 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand, resulting in an increase in additional paid-in capital of approximately $104 thousand.
		Also in the year ended December 31, 2013 a total of 3,098,500 warrants were exercised for 3,098,500 common shares having a par value of $1 thousand in aggregate, for cash consideration of approximately $1,465 thousand, resulting in an increase in additional paid-in capital of approximately $1,464 thousand. In the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

Additional_PaidIn_Capital

Additional Paid-In Capital	12 Months Ended
	Dec. 31, 2013
Additional Paid-In Capital [Text Block]	'
	10	Additional Paid-In Capital
		Stock Options
		In November 2006, the Company adopted the 2006 Stock Incentive Plan ("Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant.
		At the Annual General Meeting on September 8, 2008 the shareholders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008.
		A modification was made to the 2006 Stock Option Plan. The life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification.
		At the Annual General Meeting on June 3, 2010, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 2,074,000 to 3,308,127, or 10% of the Company’s issued and outstanding shares as of April 5, 2010.
		At the Annual General Meeting on May 7, 2013, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 3,308,127 to 5,030,292, or 10% of the Company’s issued and outstanding shares as of March 15, 2013.
		On June 13, 2012 the Company granted an aggregate of 40,000 stock options to two employees to purchase common shares. The stock options are exercisable at $0.51 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:
		Expected volatility	83%
		Expected life	3.1 years
		Risk-free interest rate	0.40%
		Dividend yield	nil
	On August 8, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.55 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand, using the following assumptions:
		Expected volatility	81%
		Expected life	1.8 years
		Risk-free interest rate	0.38%
		Dividend yield	nil
	On December 4, 2012 the Company granted 30,000 stock options to an employee who is also a director and 25,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.60 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $15 thousand, using the following assumptions:
		Expected volatility	78%
		Expected life	3.1 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
	On December 12, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.62 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:
		Expected volatility	70%
		Expected life	1.8 years
		Risk-free interest rate	0.25%
		Dividend yield	nil
		On April 24, 2013 the Company granted 480,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest on December 31, 2015. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $157 thousand, using the following assumptions:
		Expected volatility	78%
		Expected life	3.83 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
	On April 24, 2013 the Company granted 200,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $59 thousand, using the following assumptions:
		Expected volatility	77%
		Expected life	3.13 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
	On August 6, 2013 the Company granted 35,000 stock options to a non-employee director to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $9 thousand, using the following assumptions:
		Expected volatility	75%
		Expected life	3.13 years
		Risk-free interest rate	0.62%
		Dividend yield	nil
	On December 3, 2013 the Company granted 75,000 stock options to a non-employee director to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions:
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.58%
		Dividend yield	nil
		On December 3, 2013 the Company granted 100,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $21 thousand, using the following assumptions:
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.58%
		Dividend yield	nil
	On December 6, 2013 the Company granted an aggregate of 100,000 stock options to four employees to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $21 thousand, using the following assumptions:
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.64%
		Dividend yield	nil
	During the year ended December 31, 2013 a total of 75,000 (2012 – 50,000) stock options were exercised for 75,000 (2012 – 50,000) common shares having a par value of $0 thousand (2012 - $Nil) in aggregate, for cash consideration of $31 thousand (2012 - $28 thousand), resulting in an increase in additional paid-in capital of $31 thousand (2012 – $28 thousand). The intrinsic value of the stock options exercised, as at the dates of exercise, totaled $20 thousand.
		Information with respect to employees and directors stock option activity for 2012 and 2013 is as follows:
							Weighted average
				Number of options			exercise price
							$
		Outstanding – January 1, 2012		898,088			0.6
	Granted		95,000			0.56
	Forfeited		(45,000	)		(0.49	)
	Expired		(32,500	)		(1.15	)
	Exercised		-			-
	Outstanding – December 31, 2012		915,588			0.59
	Granted		990,000			0.61
	Forfeited		(45,000	)		(0.48	)
	Expired		(238,088	)		(0.80	)
	Exercised		(25,000	)		(0.31	)
	Outstanding – December 31, 2013		1,597,500			0.58
Information with respect to consultant’s stock option activity for 2012 and 2013 is as follows:
						Weighted average
			Number of options			exercise price
						$
	Outstanding – January 1, 2012		100,000			0.51
	Granted		100,000			0.59
	Forfeited		-			-
	Expired		-			-
	Exercised		(50,000	)		(0.55	)
	Outstanding – December 31, 2012		150,000			0.55
	Granted		-			-
	Forfeited		-			-
	Expired		-			-
	Exercised		(50,000	)		(0.47	)
	Outstanding – December 31, 2013		100,000			0.59
	Details of stock options outstanding as at December 31, 2013 are as follows:
		Outstanding options								Exercisable options
					Weighted			Weighted			Weighted
					average			average	Aggregate		average	Aggregate
Exercise		Number of			remaining			exercise	intrinsic	Number of	exercise	intrinsic
prices		options			contractual life			price	value	options	price	value
$					(years)			$	$		$	$
0.37		75,000			0.07			0.02		75,000	0.04
0.45		100,000			0.08			0.03		100,000	0.06
0.51		20,000			0.04			0.01		15,000	0.01
0.52		50,000			0.07			0.02		50,000	0.04
0.52		275,000			0.81			0.08		-	-
0.54		182,500			0.31			0.06		182,500	0.14
0.55		50,000			0.05			0.02		50,000	0.04
0.58		35,000			0.1			0.01		-	-
0.6		55,000			0.13			0.02		27,500	0.02
0.61		125,000			0.07			0.04		125,000	0.11
0.62		50,000			0.06			0.02		50,000	0.04
0.65		480,000			1.23			0.18		-	-
0.65		200,000			0.51			0.08		50,000	0.04
		1,697,500			3.53			0.58	47,162	725,000	0.54	34,513
Stock-based compensation expense recognized in 2013 with regards to the stock options was $114 thousand (2012 - $59 thousand). As of December 31, 2013, total unrecognized compensation expense related to unvested stock options was $228 thousand (2012 - $72 thousand), of which $Nil (2012 - $17 thousand) relates to options granted to consultants. The amount of $228 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $228 thousand being charged to stock based compensation expense.
	Warrants
	On December 16, 2013 the Company issued approximately 7.9 million stock purchase warrants exercisable into approximately 7.9 million common shares at $0.5646 per share which expire on December 16, 2018. The stock purchase warrants were issued in connection with the December 16, 2013 registered public offering described in note 9. The stock purchase warrants were valued at $1,305 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:
	Expected volatility	80%
	Expected life	5 years
	Risk-free interest rate	1.55%
	Dividend yield	nil
On December 16, 2013 the Company issued approximately 0.5 million agents’ stock purchase warrants exercisable into approximately 0.5 million common shares at $0.5646 per share which expire on December 11, 2017. The stock purchase warrants were issued in connection with the December 16, 2013 registered public offering described in note 9. The stock purchase options were valued at $100 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:
	Expected volatility	72%
	Expected life	4 years
	Risk-free interest rate	1.12%
	Dividend yield	nil
During the year ended December 31, 2013 no agents’ warrants were exercised. During the year ended December 31, 2012 a total of 219,313 agents’ warrants were exercised for 219,313 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand, resulting in an increase in additional paid-in capital of approximately $104 thousand.
Also in the year ended December 31, 2013 a total of 3,098,500 warrants were exercised for 3,098,500 common shares having a par value of $1 thousand in aggregate, for cash consideration of approximately $1,465 thousand, resulting in an increase in additional paid-in capital of approximately $1,464 thousand. In the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.
	Information with respect to warrant activity for 2012 and 2013 is as follows:
			Number of			Weighted average
			warrants			exercise price
			(All Exercisable)			$
	Outstanding – January 1, 2012		19,373,078			0.7083
	Agents’ warrants exercised		(219,313	)		(0.4700	)
	Exercised		(1,205,668	)		(0.4800	)
	Expired		(11,843,932	)		(0.8000	)
	Outstanding - December 31, 2012		6,104,165			0.5938
	Warrants attached to registered public offering		7,920,346			0.5646
	Agents’ warrants attached to registered public offering		475,221			0.5646
	Exercised		(3,098,500	)		(0.4741	)
	Agents’ warrants expired		(257,500	)		(0.4741	)
	Outstanding - December 31, 2013		11,143,732			0.6079

Income_Tax

Income Tax	12 Months Ended
	Dec. 31, 2013
Income Tax [Text Block]	'
	11	Income Taxes
		Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows:
				2013			2012
		Statutory income taxes	$	(442	)	$	(605	)
		Net operating losses for which no tax benefits have been recorded		278			368
		Excess of depreciation over capital cost allowance		11			3
		Non-deductible expenses		56			18
		Undeducted research and development expenses		142			273
		Investment tax credit		(45	)		(57	)
			$	-		$	-
	The major components of the deferred tax assets classified by the source of temporary differences are as follows:
				2013			2012
		Leasehold improvements and equipment	$	14		$	13
		Net operating losses carryforward		2,407			2,278
		Undeducted research and development expenses		1,283			1,301
		Non-refundable tax credits carryforward		1,098			914
				4,802			4,506
		Valuation allowance		(4,802	)		(4,506	)
			$	-		$	-
	The valuation allowance at December 31, 2012 was $4,506 thousand. The net change in the valuation allowance during the period ended December 31, 2013, was an increase of $296 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2013.
		There were Canadian and provincial net operating losses of approximately $8,874 thousand (2012 - $8,390 thousand) and $9,040 thousand (2012 - $8,566 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2033. A portion of the net operating losses may expire before they can be utilized.
		As at December 31, 2013, the Company had non-refundable tax credits of $1,098 thousand (2012 - $914 thousand) of which $22 thousand is expiring in 2017, $212 thousand is expiring in 2018, $186 thousand is expiring in 2019, $158 thousand is expiring in 2020, $169 thousand is expiring in 2021, $232 thousand is expiring in 2022 and $119 thousand is expiring in 2023 and undeducted research and development expenses of $4,354 thousand (2012 - $4,464 thousand) with no expiration date.
		The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.
		Unrecognized Tax Benefits
		The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
		Tax Years and Examination
		The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2013:
	Tax Jurisdictions		Tax Years
	Federal - Canada		2011 and onward
	Provincial - Quebec		2011 and onward
	Federal - USA		2011 and onward

Statement_of_Cash_Flows_Inform

Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2013
Statement of Cash Flows Information [Text Block]	'
	12	Statement of Cash Flows Information
		In US$ thousands		2013		2012
		Additional Cash Flow Information:
		Interest paid	$	5	$	3

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Text Block]	'
	13	Related Party Transactions
		Included in management salaries are $10 thousand (2012 - $6 thousand) for options granted to the Chief Executive Officer, $39 thousand (2012 - $Nil thousand) for options granted to the Chief Operating Officer, and $29 thousand (2012 - $6 thousand) for options granted to the Chief Financial Officer under the 2006 Stock Option Plan and $10 thousand (2012 - $23 thousand) for options granted to non-employee directors.
		Included in general and administrative expenses are director fees of $80 thousand (2012 - $114 thousand) comprising an annual stipend and for attendance at board meetings and audit committee meetings.
		The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

Basic_and_Diluted_Loss_Per_Com

Basic and Diluted Loss Per Common Share	12 Months Ended
	Dec. 31, 2013
Basic and Diluted Loss Per Common Share [Text Block]	'
	14	Basic and Diluted Loss Per Common Share
		Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Text Block]	'
	15	Subsequent Events
		On January 13, 2014 the Company announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. for two new products utilizing IntelGenx' proprietary oral drug delivery platforms. Under the terms of the agreement, Par has obtained certain exclusive rights to market and sell IntelGenx' products in the USA. In exchange IntelGenx will receive upfront and milestone payments, together with a share of the profits upon commercialization. In accordance with confidentiality clauses contained in the agreement, the specifics of the product descriptions, platform technologies and financial terms were not disclosed.
		Subsequent to the year ended December 31, 2013 an aggregate of 1,616,388 warrants were exercised for 1,616,388 common shares having a par value of $0 thousand for cash consideration of approximately $1 million, resulting in an increase in additional paid-in capital of approximately $1 million.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Revenue Recognition [Policy Text Block]	'
		Revenue Recognition
		The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.
		IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.
Product Sales [Policy Text Block]	'
		Product Sales:
		The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $171 thousand in 2013.
		Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $308 thousand in 2013 and has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.
Use of Estimates [Policy Text Block]	'
		Use of Estimates
		The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.
		Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
Cash and Cash Equivalents [Policy Text Block]	'
		Cash and Cash Equivalents
		Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.
Accounts Receivable [Policy Text Block]	'
		Accounts Receivable
		The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2013 accounts receivable (2012 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.
Investment Tax Credits [Policy Text Block]	'
		Investment Tax Credits
		Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.
Leasehold Improvements and Equipment [Policy Text Block]	'
		Leasehold Improvements and Equipment
		Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:
		On the declining balance method -
		Laboratory and office equipment	20%
		Computer equipment	30%
		On the straight-line method -
		Leasehold improvements	over the lease term
		Manufacturing equipment	5 – 10 years
	Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Intangible Assets [Policy Text Block]	'
	Intangible Assets
	Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
Impairment of Long-lived Assets [Policy Text Block]	'
	Impairment of Long-lived Assets
	Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.
Foreign Currency Translation [Policy Text Block]	'
		Foreign Currency Translation
		The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:
	Assets and liabilities - at exchange rates in effect at the balance sheet date;
	Revenue and expenses - at average exchange rates prevailing during the year;
	Equity - at historical rates.
	Gains and losses arising from foreign currency translation are included in other comprehensive income.
Income Taxes [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Unrecognized Tax Benefits [Policy Text Block]	'
	Unrecognized Tax Benefits
	The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
	Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
Share-Based Payments [Policy Text Block]	'
		Share-Based Payments
		The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.
		The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.
Loss Per Share [Policy Text Block]	'
		Loss Per Share
		Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.
Fair Value Measurements [Policy Text Block]	'
		Fair Value Measurements
		ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		Level 1:	Quoted market prices in active markets for identical assets or liabilities.
		Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
		Level 3:	Unobservable inputs that are not corroborated by market data.
	In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2013.
Fair Value of Financial Instruments [Policy Text Block]	'
	Fair Value of Financial Instruments
	The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
Recent Accounting Pronouncements [Policy Text Block]	'
	Recent Accounting Pronouncements
	In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]	'
		On the declining balance method -
		Laboratory and office equipment	20%
		Computer equipment	30%
		On the straight-line method -
		Leasehold improvements	over the lease term
		Manufacturing equipment	5 – 10 years

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Leasehold Improvements and Equipment [Table Text Block]	'
								2013		2012
		In US$ thousands				Accumulated		Net Carrying		Net Carrying
				Cost		Depreciation		Amount		Amount
		Manufacturing equipment	$	446	$	0	$	446	$	225
		Laboratory and office equipment		398		277		121		153
		Computer equipment		46		35		11		9
		Leasehold improvements - current premises		58		58		0		0
		Leasehold improvements - future premises		10		0		10		0
			$	958	$	370	$	588	$	387

Capital_Stock_Tables

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Stock by Class [Table Text Block]	'
				2013		2011
		Authorized -
		100,000,000 common shares of $0.00001 par value
		20,000,000 preferred shares of $0.00001 par value
		Issued -
		60,984,267 (December 31, 2012 - 49,890,421) common shares	$	610	$	499

Additional_PaidIn_Capital_Tabl

Additional Paid-In Capital (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Stock Options Valuation - June13, 2012 [Table Text Block]	'
		Expected volatility	83%
		Expected life	3.1 years
		Risk-free interest rate	0.40%
		Dividend yield	nil
Schedule of Stock Options Valuation - August 8, 2012 [Table Text Block]	'
		Expected volatility	81%
		Expected life	1.8 years
		Risk-free interest rate	0.38%
		Dividend yield	nil
Schedule of Stock Options Valuation - December 4, 2012 [Table Text Block]	'
		Expected volatility	78%
		Expected life	3.1 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
Schedule of Stock Options Valuation - December 12, 2012 [Table Text Block]	'
		Expected volatility	70%
		Expected life	1.8 years
		Risk-free interest rate	0.25%
		Dividend yield	nil
Schedule of 480,000 Stock Options Valuation - April 24, 2013 [Table Text Block]	'
		Expected volatility	78%
		Expected life	3.83 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
Schedule of 200,000 Stock Options Valuation - April 24, 2013 [Table Text Block]	'
		Expected volatility	77%
		Expected life	3.13 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
Schedule of 35,000 Stock Options Valuation - August 6, 2013 [Table Text Block]	'
		Expected volatility	75%
		Expected life	3.13 years
		Risk-free interest rate	0.62%
		Dividend yield	nil
Schedule of 75,000 Stock Options Valuation - December 3, 2013 [Table Text Block]	'
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.58%
		Dividend yield	nil
Schedule of 100,000 Stock Options Valuation - December 3, 2013 [Table Text Block]	'
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.58%
		Dividend yield	nil
Schedule of 100,000 Stock Options Valuation - December 6, 2013 [Table Text Block]	'
		Expected volatility	67%
		Expected life	3.13 years
		Risk-free interest rate	0.64%
		Dividend yield	nil
Schedule of Stock Option Activity to Employees and Directors[Table Text Block]	'
							Weighted average
				Number of options			exercise price
							$
		Outstanding – January 1, 2012		898,088			0.6
		Granted		95,000			0.56
		Forfeited		(45,000	)		(0.49	)
		Expired		(32,500	)		(1.15	)
		Exercised		-			-
		Outstanding – December 31, 2012		915,588			0.59
		Granted		990,000			0.61
		Forfeited		(45,000	)		(0.48	)
		Expired		(238,088	)		(0.80	)
		Exercised		(25,000	)		(0.31	)
		Outstanding – December 31, 2013		1,597,500			0.58
Schedule of Stock Option Activity to Consultant's [Table Text Block]	'
							Weighted average
				Number of options			exercise price
							$
		Outstanding – January 1, 2012		100,000			0.51
		Granted		100,000			0.59
		Forfeited		-			-
		Expired		-			-
		Exercised		(50,000	)		(0.55	)
		Outstanding – December 31, 2012		150,000			0.55
		Granted		-			-
		Forfeited		-			-
		Expired		-			-
		Exercised		(50,000	)		(0.47	)
		Outstanding – December 31, 2013		100,000			0.59
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]	'
			Outstanding options								Exercisable options
						Weighted			Weighted			Weighted
						average			average	Aggregate		average	Aggregate
	Exercise		Number of			remaining			exercise	intrinsic	Number of	exercise	intrinsic
	prices		options			contractual life			price	value	options	price	value
	$					(years)			$	$		$	$
	0.37		75,000			0.07			0.02		75,000	0.04
	0.45		100,000			0.08			0.03		100,000	0.06
	0.51		20,000			0.04			0.01		15,000	0.01
	0.52		50,000			0.07			0.02		50,000	0.04
	0.52		275,000			0.81			0.08		-	-
	0.54		182,500			0.31			0.06		182,500	0.14
	0.55		50,000			0.05			0.02		50,000	0.04
	0.58		35,000			0.1			0.01		-	-
	0.6		55,000			0.13			0.02		27,500	0.02
	0.61		125,000			0.07			0.04		125,000	0.11
	0.62		50,000			0.06			0.02		50,000	0.04
	0.65		480,000			1.23			0.18		-	-
	0.65		200,000			0.51			0.08		50,000	0.04
			1,697,500			3.53			0.58	47,162	725,000	0.54	34,513
Schedule of Warrants Valuation - December 16, 2013 [Table Text Block]	'
		Expected volatility	80%
		Expected life	5 years
		Risk-free interest rate	1.55%
		Dividend yield	nil
Schedule of 0.5 million Warrants Valuation - December 16, 2013 [Table Text Block]	'
		Expected volatility	72%
		Expected life	4 years
		Risk-free interest rate	1.12%
		Dividend yield	nil
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	'
				Number of			Weighted average
				warrants			exercise price
				(All Exercisable)			$
		Outstanding – January 1, 2012		19,373,078			0.7083
		Agents’ warrants exercised		(219,313	)		(0.4700	)
		Exercised		(1,205,668	)		(0.4800	)
		Expired		(11,843,932	)		(0.8000	)
		Outstanding - December 31, 2012		6,104,165			0.5938
		Warrants attached to registered public offering		7,920,346			0.5646
		Agents’ warrants attached to registered public offering		475,221			0.5646
		Exercised		(3,098,500	)		(0.4741	)
		Agents’ warrants expired		(257,500	)		(0.4741	)
		Outstanding - December 31, 2013		11,143,732			0.6079

Income_Tax_Tables

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
				2013			2012
		Statutory income taxes	$	(442	)	$	(605	)
		Net operating losses for which no tax benefits have been recorded		278			368
		Excess of depreciation over capital cost allowance		11			3
		Non-deductible expenses		56			18
		Undeducted research and development expenses		142			273
		Investment tax credit		(45	)		(57	)
			$	-		$	-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
				2013			2012
		Leasehold improvements and equipment	$	14		$	13
		Net operating losses carryforward		2,407			2,278
		Undeducted research and development expenses		1,283			1,301
		Non-refundable tax credits carryforward		1,098			914
				4,802			4,506
		Valuation allowance		(4,802	)		(4,506	)
			$	-		$	-

Statement_of_Cash_Flows_Inform1

Statement of Cash Flows Information (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
		In US$ thousands		2013		2012
		Additional Cash Flow Information:
		Interest paid	$	5	$	3

Nature_of_Business_Narrative_D

Nature of Business (Narrative) (Details)	12 Months Ended
	Dec. 31, 2013
Nature Of Business 1	5
Nature Of Business 2	4

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	D
Summary Of Significant Accounting Policies 1	45
Summary Of Significant Accounting Policies 2	$800,000
Summary Of Significant Accounting Policies 3	200,000
Summary Of Significant Accounting Policies 4	500,000
Summary Of Significant Accounting Policies 5	500,000
Summary Of Significant Accounting Policies 6	250,000
Summary Of Significant Accounting Policies 7	2,000,000
Summary Of Significant Accounting Policies 8	26,500,000
Summary Of Significant Accounting Policies 9	4,000,000
Summary Of Significant Accounting Policies 10	1,000,000
Summary Of Significant Accounting Policies 11	23,500,000
Summary Of Significant Accounting Policies 12	171,000
Summary Of Significant Accounting Policies 13	1,000,000
Summary Of Significant Accounting Policies 14	308,000
Summary Of Significant Accounting Policies 15	616,000
Summary Of Significant Accounting Policies 16	0
Summary Of Significant Accounting Policies 17	1,282,000
Summary Of Significant Accounting Policies 18	$1,000,000
Summary Of Significant Accounting Policies 19	50.00%

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Leasehold Improvements And Equipment 1	$10

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
	M
Intangible Assets 1	$79
Intangible Assets 2	$116
Intangible Assets 3	100.00%
Intangible Assets 4	39

Deferred_License_Revenue_Narra

Deferred License Revenue (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	M
Deferred License Revenue 1	$1,000,000
Deferred License Revenue 2	39
Deferred License Revenue 3	$616,000

Commitments_Narrative_Details

Commitments (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
	M
	Y
Commitments 1	3,500
Commitments 2	6,425
Commitments 3	6,410
Commitments 4	6,420
Commitments 5	16,000
Commitments 6	10
Commitments 7	6
Commitments 8	$15
Commitments 9	4
Commitments 10	2
Commitments 11	200
Commitments 12	10.00%
Commitments 13	$147

Capital_Stock_Narrative_Detail

Capital Stock (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	M
Capital Stock 1	7,900,000
Capital Stock 2	$0.44
Capital Stock 3	7,900,000
Capital Stock 4	$3,500,000
Capital Stock 5	0.5646
Capital Stock 6	60
Capital Stock 7	1,808,000
Capital Stock 8	210,000
Capital Stock 9	6.00%
Capital Stock 10	35,000
Capital Stock 11	475,221
Capital Stock 12	6.00%
Capital Stock 13	0.5646
Capital Stock 14	48
Capital Stock 15	272,000
Capital Stock 16	75,000
Capital Stock 17	50,000
Capital Stock 18	75,000
Capital Stock 19	50,000
Capital Stock 20	0
Capital Stock 21	0
Capital Stock 22	31,000
Capital Stock 23	28,000
Capital Stock 24	31,000
Capital Stock 25	28,000
Capital Stock 26	219,313
Capital Stock 27	219,313
Capital Stock 28	0
Capital Stock 29	104,000
Capital Stock 30	104,000
Capital Stock 31	3,098,500
Capital Stock 32	3,098,500
Capital Stock 33	1,000
Capital Stock 34	1,465,000
Capital Stock 35	1,464,000
Capital Stock 36	1,205,668
Capital Stock 37	491,382
Capital Stock 38	491,382
Capital Stock 39	0
Capital Stock 40	233,000
Capital Stock 41	233,000
Capital Stock 42	714,286
Capital Stock 43	234,698
Capital Stock 44	$0

Additional_PaidIn_Capital_Narr

Additional Paid-In Capital (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
	M
Additional Paid-in Capital 1	1,600,749
Additional Paid-in Capital 2	100.00%
Additional Paid-in Capital 3	10
Additional Paid-in Capital 4	24
Additional Paid-in Capital 5	100.00%
Additional Paid-in Capital 6	1,600,749
Additional Paid-in Capital 7	2,074,000
Additional Paid-in Capital 8	10.00%
Additional Paid-in Capital 9	10
Additional Paid-in Capital 10	5
Additional Paid-in Capital 11	2,074,000
Additional Paid-in Capital 12	3,308,127
Additional Paid-in Capital 13	10.00%
Additional Paid-in Capital 14	3,308,127
Additional Paid-in Capital 15	5,030,292
Additional Paid-in Capital 16	10.00%
Additional Paid-in Capital 17	40,000
Additional Paid-in Capital 18	$0.51
Additional Paid-in Capital 19	2
Additional Paid-in Capital 20	25.00%
Additional Paid-in Capital 21	$10,000
Additional Paid-in Capital 22	50,000
Additional Paid-in Capital 23	$0.55
Additional Paid-in Capital 24	1
Additional Paid-in Capital 25	25.00%
Additional Paid-in Capital 26	12,000
Additional Paid-in Capital 27	30,000
Additional Paid-in Capital 28	25,000
Additional Paid-in Capital 29	$0.60
Additional Paid-in Capital 30	2
Additional Paid-in Capital 31	25.00%
Additional Paid-in Capital 32	15,000
Additional Paid-in Capital 33	50,000
Additional Paid-in Capital 34	$0.62
Additional Paid-in Capital 35	1
Additional Paid-in Capital 36	25.00%
Additional Paid-in Capital 37	10,000
Additional Paid-in Capital 38	480,000
Additional Paid-in Capital 39	$0.65
Additional Paid-in Capital 40	157,000
Additional Paid-in Capital 41	200,000
Additional Paid-in Capital 42	$0.65
Additional Paid-in Capital 43	2
Additional Paid-in Capital 44	25.00%
Additional Paid-in Capital 45	59,000
Additional Paid-in Capital 46	35,000
Additional Paid-in Capital 47	$0.65
Additional Paid-in Capital 48	2
Additional Paid-in Capital 49	25.00%
Additional Paid-in Capital 50	9,000
Additional Paid-in Capital 51	75,000
Additional Paid-in Capital 52	$0.52
Additional Paid-in Capital 53	2
Additional Paid-in Capital 54	25.00%
Additional Paid-in Capital 55	16,000
Additional Paid-in Capital 56	100,000
Additional Paid-in Capital 57	$0.52
Additional Paid-in Capital 58	2
Additional Paid-in Capital 59	25.00%
Additional Paid-in Capital 60	21,000
Additional Paid-in Capital 61	100,000
Additional Paid-in Capital 62	$0.52
Additional Paid-in Capital 63	2
Additional Paid-in Capital 64	25.00%
Additional Paid-in Capital 65	21,000
Additional Paid-in Capital 66	75,000
Additional Paid-in Capital 67	50,000
Additional Paid-in Capital 68	75,000
Additional Paid-in Capital 69	50,000
Additional Paid-in Capital 70	0
Additional Paid-in Capital 71	0
Additional Paid-in Capital 72	31,000
Additional Paid-in Capital 73	28,000
Additional Paid-in Capital 74	31,000
Additional Paid-in Capital 75	28,000
Additional Paid-in Capital 76	20,000
Additional Paid-in Capital 77	114,000
Additional Paid-in Capital 78	59,000
Additional Paid-in Capital 79	228,000
Additional Paid-in Capital 80	72,000
Additional Paid-in Capital 81	0
Additional Paid-in Capital 82	17,000
Additional Paid-in Capital 83	228,000
Additional Paid-in Capital 84	228,000
Additional Paid-in Capital 85	7,900,000
Additional Paid-in Capital 86	7,900,000
Additional Paid-in Capital 87	$0.56
Additional Paid-in Capital 88	1,305,000
Additional Paid-in Capital 89	500,000
Additional Paid-in Capital 90	500,000
Additional Paid-in Capital 91	$0.56
Additional Paid-in Capital 92	100,000
Additional Paid-in Capital 93	219,313
Additional Paid-in Capital 94	219,313
Additional Paid-in Capital 95	0
Additional Paid-in Capital 96	104,000
Additional Paid-in Capital 97	104,000
Additional Paid-in Capital 98	3,098,500
Additional Paid-in Capital 99	3,098,500
Additional Paid-in Capital 100	1,000
Additional Paid-in Capital 101	1,465,000
Additional Paid-in Capital 102	1,464,000
Additional Paid-in Capital 103	1,205,668
Additional Paid-in Capital 104	491,382
Additional Paid-in Capital 105	491,382
Additional Paid-in Capital 106	0
Additional Paid-in Capital 107	233,000
Additional Paid-in Capital 108	233,000
Additional Paid-in Capital 109	714,286
Additional Paid-in Capital 110	234,698
Additional Paid-in Capital 111	$0

Income_Tax_Narrative_Details

Income Tax (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Income Tax 1	$4,506
Income Tax 2	296
Income Tax 3	8,874
Income Tax 4	8,390
Income Tax 5	9,040
Income Tax 6	8,566
Income Tax 7	1,098
Income Tax 8	914
Income Tax 9	22
Income Tax 10	212
Income Tax 11	186
Income Tax 12	158
Income Tax 13	169
Income Tax 14	232
Income Tax 15	119
Income Tax 16	4,354
Income Tax 17	$4,464

Related_Party_Transactions_Nar

Related Party Transactions (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Related Party Transactions 1	$10
Related Party Transactions 2	6
Related Party Transactions 3	39
Related Party Transactions 4	0
Related Party Transactions 5	29
Related Party Transactions 6	6
Related Party Transactions 7	10
Related Party Transactions 8	23
Related Party Transactions 9	80
Related Party Transactions 10	$114

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Subsequent Events 1	1,616,388
Subsequent Events 2	1,616,388
Subsequent Events 3	$0
Subsequent Events 4	1,000,000
Subsequent Events 5	$1,000,000

Schedule_of_Estimated_Useful_L

Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 1	20.00%
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 2	30.00%
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 3	$5
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 4	10

Schedule_of_Leasehold_Improvem

Schedule of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1	$446
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3	446
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4	225
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5	398
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6	277
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7	121
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8	153
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9	46
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10	35
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11	11
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12	9
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13	58
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14	58
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17	10
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19	10
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 21	958
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 22	370
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 23	588
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 24	$387

Schedule_of_Stock_by_Class_Det

Schedule of Stock by Class (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Capital Stock Schedule Of Stock By Class 1	100,000,000
Capital Stock Schedule Of Stock By Class 2	$0.00
Capital Stock Schedule Of Stock By Class 3	20,000,000
Capital Stock Schedule Of Stock By Class 4	0.00001
Capital Stock Schedule Of Stock By Class 5	60,984,267
Capital Stock Schedule Of Stock By Class 6	49,890,421
Capital Stock Schedule Of Stock By Class 7	610
Capital Stock Schedule Of Stock By Class 8	$499

Schedule_of_Stock_Options_Valu

Schedule of Stock Options Valuation - June13, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 1	83.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 3	0.40%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 4	$0

Schedule_of_Stock_Options_Valu1

Schedule of Stock Options Valuation - August 8, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 1	81.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 3	0.38%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4	$0

Schedule_of_Stock_Options_Valu2

Schedule of Stock Options Valuation - December 4, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 1	78.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 3	0.34%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4	$0

Schedule_of_Stock_Options_Valu3

Schedule of Stock Options Valuation - December 12, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 1	70.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 3	0.25%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4	$0

Schedule_of_480000_Stock_Optio

Schedule of 480,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 1	78.00%
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 2	3.83
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 3	0.34%
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 4	$0

Schedule_of_200000_Stock_Optio

Schedule of 200,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 1	77.00%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 2	3.13
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 3	0.34%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 4	$0

Schedule_of_35000_Stock_Option

Schedule of 35,000 Stock Options Valuation - August 6, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 1	75.00%
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 2	3.13
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 3	0.62%
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 4	$0

Schedule_of_75000_Stock_Option

Schedule of 75,000 Stock Options Valuation - December 3, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 1	67.00%
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 2	3.13
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 3	0.58%
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 4	$0

Schedule_of_100000_Stock_Optio

Schedule of 100,000 Stock Options Valuation - December 3, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 1	67.00%
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 2	3.13
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 3	0.58%
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 4	$0

Schedule_of_100000_Stock_Optio1

Schedule of 100,000 Stock Options Valuation - December 6, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 1	67.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 2	3.13
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 3	0.64%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 4	$0

Schedule_of_Stock_Option_Activ

Schedule of Stock Option Activity to Employees and Directors[Table Text Block] (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 1	$898,088
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 2	0.6
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 3	95,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 4	0.56
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 5	-45,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 6	-0.49
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 7	-32,500
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 8	-1.15
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 9	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 10	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 11	915,588
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 12	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 13	990,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 14	0.61
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 15	-45,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 16	-0.48
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 17	-238,088
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 18	-0.8
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 19	-25,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 20	-0.31
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 21	$1,597,500
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 22	0.58

Schedule_of_Stock_Option_Activ1

Schedule of Stock Option Activity to Consultant's (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 1	$100,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 2	0.51
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 3	100,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 4	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 5	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 6	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 7	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 8	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 9	-50,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 10	-0.55
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 11	150,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 12	0.55
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 13	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 14	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 15	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 16	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 17	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 18	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 19	-50,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 20	-0.47
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 21	$100,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 22	0.59

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2	$75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3	0.07
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5	75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7	0.45
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8	100,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9	0.08
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10	0.03
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11	100,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14	20,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17	15,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19	0.52
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21	0.07
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25	0.52
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26	275,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27	0.81
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28	0.08
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32	182,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35	182,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36	0.14
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39	0.05
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44	35,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45	0.1
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49	0.6
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50	55,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51	0.13
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53	27,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57	0.07
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60	0.11
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67	0.65
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68	480,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69	1.23
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 70	0.18
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 71	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 72	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 73	0.65
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 74	200,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 75	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 76	0.08
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 77	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 78	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 79	1,697,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 80	3.53
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 81	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 82	47,162
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 83	725,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 84	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 85	$34,513

Schedule_of_Warrants_Valuation

Schedule of Warrants Valuation - December 16, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 1	80.00%
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 2	5
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 3	1.55%
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 4	$0

Schedule_of_05_million_Warrant

Schedule of 0.5 million Warrants Valuation - December 16, 2013 (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 1	72.00%
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 2	4
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 3	1.12%
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 4	$0

Schedule_of_Stockholders_Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$19,373,078
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	0.7083
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	-219,313
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	-0.47
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	-1,205,668
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	-0.48
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	-11,843,932
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	-0.8
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	6,104,165
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	0.5938
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	7,920,346
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	0.5646
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	475,221
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	0.5646
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15	-3,098,500
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16	-0.4741
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17	-257,500
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18	-0.4741
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 19	$11,143,732
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 20	0.6079

Schedule_of_Effective_Income_T

Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1	$278
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2	368
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3	11
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4	3
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5	56
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6	18
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7	142
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8	273
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9	-45
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10	-57
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12	$0

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1	$14
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2	13
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3	2,407
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4	2,278
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5	1,283
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6	1,301
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7	1,098
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8	914
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9	4,802
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10	4,506
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11	-4,802
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12	-4,506
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13	0
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14	$0

Schedule_of_Cash_Flow_Suppleme

Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1	$5
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2	$3